Solid Biosciences Inc

NASDAQ: SLDB
$10.10
-$0.13 (-1.3%)
Closing price May 3, 2024

SLDB Chart and Intraday Price

SLDB Company Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Address 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE, MA, US
Fiscal Year End December
Latest Quarter 9/30/2023
Market Cap 365.78M USD
Shares Outstanding 37,439,000
Solid Biosciences Inc. focuses on creating innovative therapies for neuromuscular and cardiac diseases, including Duchenne muscular dystrophy and Friedreich’s ataxia. With a leading product candidate, SGT-003, aimed at Duchenne muscular dystrophy, the company is at the forefront of gene therapy research. It also explores treatments for cardiac conditions like BAG3-mediated dilated cardiomyopathy. Based in Massachusetts, Solid Biosciences is pioneering in dual gene expression technology and has partnerships to advance gene therapy development.

SLDB Articles

Insider Buying: Taking a Controlling Stake in a Struggling Retailer?
A beneficial owner stepped up and took a controlling stake in a struggling retailer, while public offerings of stock prompted insider buying at some biotech companies.
Trey Thoelcke
Published:

More Big Warren Buffett Purchases Highlight Recent Insider Buying
Insider buying was somewhat slow in the middle of January, but some purchases by Warren Buffett's Berkshire Hathaway made headlines.
Trey Thoelcke
Published: